On the Horizon: Strategies for Surgical Success of Durable Anti-VEGF Delivery in nAMD and DME

On the Horizon: Strategies for Surgical Success of Durable Anti-VEGF Delivery in nAMD and DME

On the Horizon: Strategies for Surgical Success of Durable Anti-VEGF Delivery in nAMD and DME
RestartResume

See the latest surgical approaches for durable VEGF suppression in action and learn about new technologies that are coming to the office and the OR. 

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The quest for durable VEGF-suppression in neovascular AMD and diabetic macular edema has led to significant advances in the operating room for surgical retina specialists. What are these new methods, and what do surgeons need to know to ensure a successful procedure? Listen to pro tips from Drs. Carl Awh and Peter Campochiaro and see demonstrations of the new techniques. How will your patients benefit from the introduction of durable VEGF suppression into clinical practice?  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Carl C. Awh, MD
    President
    Tennessee Retina, PC
    Nashville, TN

    Contracted Research: Adverum, Genentech
    Consulting Fees: Genentech

    Faculty:
    Peter A. Campochiaro, MD
    Eccles Professor of Ophthalmology and Neuroscience
    Johns Hopkins University School of Medicine
    Baltimore, MD

    Consulting Fees: Aerpio Pharmaceuticals, Allegro Pharmaceuticals, AsclepiX Therapeutics, Ashvattha Therapeutics, Bausch + Lomb, Clearside Biomedical, Exonate Ltd., Genentech/Roche, Merck & Co, Perfuse Therapeutics, Regeneron, Wave Life Sciences
    Contracted Research: Aerpio Pharmaceuticals, Ashvattha Therapeutics, Genentech/Roche, Mallinckrodt, Oxford Biomedica, REGENXBIO, Sanofi Genzyme
    Ownership Interest: Allegro Pharmaceuticals, Graybug

    Reviewers/Content Planners/Authors

    • Stephen Chavez has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Stephanie Wenick, MPhil, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify keys to the surgical success of anti-VEGF management strategies in development for patients with nAMD or DME who may benefit from sustained treatment
    • Compare and contrast injection strategies between traditional injectable agents and refillable device strategies in development that are designed to decrease anti-VEGF treatment burden 
  • Target Audience

    This activity is designed to meet the educational needs of ophthalmologists, retina specialists, and other eye health professionals.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by independent educational grants from Genentech, a member of the Roche Group, and F. Hoffmann-La Roche Ltd.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free